Skip to main content
    K

    Karyopharm Therapeutics Inc (KPTI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.35
    +0.04 (+11.37%)

    Market Cap: $9.69M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    +3.23%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.31
    Range$-1.37 - $-1.26
    2 analysts
    EPS Revisions
    2
    0
    7d
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.21-8.4%
    60d ago$-1.21-8.4%
    30d ago$-1.21-8.4%
    7d ago$-1.46+9.7%
    Current$-1.31
    Revenue Consensus
    $34M
    Range$32M - $35M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.70
    Range$-1.86 - $-1.53
    2 analysts
    Revenue Consensus
    $38M
    Range$34M - $41M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.70---
    Sep 26EST
    		-$-1.31---
    Jun 26
    Reported Aug 13
    		$-2.32$-1.53-51.63%Miss+43.0%
    Mar 26
    Reported May 14
    		$-1.24$-1.44+13.89%Beat+55.2%
    Dec 25
    Reported Feb 12
    		$-2.23$-2.00-11.50%Miss+38.1%
    Sep 25
    Reported Nov 3
    		$-3.82$-3.25-17.54%Miss+2.1%
    Jun 25
    Reported Aug 11
    		$-4.07$-3.91-4.09%Miss+6.2%
    Mar 25
    Reported May 12
    		$-2.77$-3.09+10.36%Beat+42.3%
    Dec 24
    Reported Feb 19
    		$-3.60$-4.03+10.67%Beat-900.0%
    Sep 24
    Reported Nov 5
    		$-3.90$-3.92+0.51%Beat+13.3%
    Jun 24
    Reported Aug 6
    		$-4.34$-4.47+2.91%Beat+0.2%
    Mar 24
    Reported May 8
    		$-4.80$-4.94+2.83%Beat-6.7%
    Dec 23
    Reported Feb 29
    		$-0.36$-0.31-16.13%Miss+94.4%
    Sep 23
    Reported Nov 2
    		$-4.50$-4.29-4.90%Miss+33.3%
    Jun 23
    Reported Aug 2
    		$-4.35$-5.04+13.69%Beat+53.2%
    Mar 23
    Reported May 4
    		$-4.50$-5.23+13.96%Beat+43.4%
    Dec 22
    Reported Feb 15
    		$-6.45$-5.38-19.89%Miss-193.5%
    Sep 22
    Reported Nov 3
    		$-6.75$-8.02+15.84%Beat+34.8%
    Jun 22
    Reported Aug 4
    		$-9.30$-9.55+2.62%Beat+12.7%
    Mar 22
    Reported May 5
    		$-7.95$-9.24+13.96%Beat+31.2%
    Dec 21
    Reported Feb 8
    		$6.90$-6.37+208.32%Beat+178.0%
    Sep 21
    Reported Nov 3
    		$-10.35$-10.27-0.78%Miss+5.5%
    Jun 21
    Reported Aug 5
    		$-10.65$-10.97+2.92%Beat-12.7%
    Mar 21
    Reported May 3
    		$-11.55$-10.75-7.44%Miss+1.3%
    Dec 20
    Reported Feb 11
    		$-8.85$-8.97+1.34%Beat+22.4%
    Sep 20
    Reported Nov 2
    		$-10.95$-10.48-4.48%Miss-9.0%
    Jun 20
    Reported Aug 4
    		$-9.45$-8.92-5.94%Miss+11.3%
    Mar 20
    Reported May 5
    		$-11.70$-10.29-13.70%Miss+28.4%
    Dec 19
    Reported Feb 13
    		$-11.40$-10.16-12.20%Miss-1087.5%
    Sep 19
    Reported Nov 4
    		$-10.05$-12.17+17.42%Beat+15.2%
    Jun 19
    Reported Aug 6
    		$-10.65$-14.29+25.47%Beat-18.3%
    Mar 19
    Reported May 9
    		$-16.35$-12.89-26.84%Miss-39.7%
    Dec 18
    Reported Feb 28
    		$-0.96$-0.85-12.94%Miss-20.0%
    Sep 18
    Reported Nov 8
    		$-11.85$-13.15+9.89%Beat-21.5%
    Jun 18
    Reported Aug 7
    		$-9.00$-12.03+25.19%Beat+6.2%
    Mar 18
    Reported May 10
    		$-11.70$-9.62-21.62%Miss-9.9%
    Dec 17
    Reported Mar 15
    		$-0.80$-0.65-23.08%Miss-23.1%
    Sep 17
    Reported Nov 2
    		$-9.75$-9.45-3.17%Miss-
    Jun 17
    Reported Aug 8
    		$-9.60$-9.77+1.74%Beat-
    Mar 17
    Reported May 4
    		$-10.65$-9.59-11.05%Miss-
    Dec 16
    Reported Mar 16
    		$-0.65$-0.66+1.52%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.04EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-153.30%Operating Margin-67.40%
    ROE-891.00%ROIC64.55%
    Financial Health
    Debt/Equity-0.46xInterest Coverage-1.03x
    Current Ratio0.79xQuick Ratio0.76x
    Trading Statistics
    Beta1.04Avg Volume1.40M
    52-Week High$10.9952-Week Low$0.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.56
    SMA 20$1.06
    SMA 50$1.54
    SMA 200$6.43
    EMA 10$0.61
    EMA 20$0.94
    EMA 50$2.12
    EMA 200$5.15

    MACD

    Line: -0.46Signal: -0.45Hist: -0.01

    ADX

    ADX: 61.4+DI: 6.5-DI: 49.7

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down100.0
    PSAR$0.81

    Bollinger Bands

    Upper Band$2.21
    Lower Band$-0.09
    %B Position21735%(Upper)
    Band Width0.19

    RSI (14-Day)

    Oversold
    16.1

    Momentum Oscillators

    Stoch %K1.8
    Stoch %D1.5
    Williams %R-97.0
    ROC (10d)-59.5%
    Momentum-0.52
    CCI (20d)-95.6
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)$0.15(43.7%)
    StdDev (20d)0.57
    Hist Vol173.4%(High)

    Volume Flow

    VWAP$0.34
    OBV-54.2M
    AD Line-24.7M
    CMF (20d)-0.324

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.9x
    VWMA (20d)$1.01

    Pivot Points

    R3$0.50
    R2$0.46
    R1$0.39
    Pivot Point$0.35
    S1$0.28
    S2$0.24
    S3$0.17

    Advanced Oscillators

    TSI-63.27
    Ultimate Osc26.2
    KST-632.44

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$33.43M$35.07M$34.08M$44.04M$37.93M$30.02M$30.54M$38.78M$42.79M$33.13M$33.75M$36.01M
    Cost of Revenue$1.08M$1.34M$1.48M$2.11M$1.05M$1.30M$1.33M$1.30M$1.47M$1.91M$1.49M$911,000
    Gross Profit$32.35M$33.72M$32.59M$41.93M$36.88M$28.71M$29.21M$37.48M$41.32M$31.21M$32.26M$35.10M
    Operating Expenses$54.87M$60.48M$50.44M$57.15M$61.27M$61.97M$60.49M$63.77M$69.44M$64.97M$70.07M$66.36M
    R&D$28.96M$33.80M$27.67M$30.54M$32.79M$34.62M$33.30M$36.13M$38.37M$35.42M$39.38M$35.55M
    SG&A$25.92M$26.68M$22.77M$26.61M$28.48M$27.35M$27.19M$27.63M$31.07M$29.55M$30.69M$30.80M
    Operating Income$-22,526,000$-26,760,000$-17,844,000$-15,220,000$-24,387,000$-33,256,000$-31,281,000$-26,283,000$-28,120,000$-33,759,000$-37,808,000$-31,260,000
    Interest Income$722,000$511,000$607,000$553,000$613,000$1.00M$1.48M$1.83M$1.93M$2.16M$2.52M$2.75M
    Interest Expense$13.14M$12.55M$74.98M$11.01M$11.23M$10.99M$11.20M$11.38M$-35,753,000$5.88M$6.21M$6.07M
    Income Before Tax$-67,023,000$-22,391,000$-102,265,000$-33,093,000$-37,212,000$-23,426,000$-30,889,000$-32,044,000$23.86M$-37,291,000$-41,707,000$-34,494,000
    Income Tax Expense$0$1,000$-67,000$34,000$40,000$36,000$-109,000$28,000$67,000$71,000$130,000$12,000
    Net Income$-67,023,000$-22,392,000$-102,198,000$-33,127,000$-37,252,000$-23,462,000$-30,780,000$-32,072,000$23.79M$-37,362,000$-41,837,000$-34,506,000
    EBITDA$-52,137,000$-7,973,000$-25,433,000$-19,754,000$-23,919,000$-11,017,000$-19,121,000$-20,532,000$-13,006,000$-34,181,000$-38,746,000$-31,822,000
    EBIT$-54,601,000$-10,349,000$-27,888,000$-22,638,000$-26,597,000$-13,432,000$-21,167,000$-22,491,000$-13,824,000$-33,563,000$-38,019,000$-31,171,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KPTI

    News

    Six analysts give Karyopharm stock a USD 11.50 consensus target

    Six analysts have set a consensus price target of USD 11.50 for Karyopharm Therapeutics stock, significantly higher than its current Nasdaq price of USD 0.32. The company, which is focused on cancer therapies...

    ad-hoc-news.de•10/15/26•Neutral

    Karyopharm Therapeutics extends forbearance period to Oct. 22 under indenture agreement

    Karyopharm Therapeutics (KPTI) has extended its forbearance period under an indenture agreement until October 22, 2026, at 11:59 p.m. ET. This extension, agreed upon by relevant parties...

    TradingView•10/14/26•Neutral

    Two Acorn funds account for one manager’s reported stake in Karyopharm (KPTI).

    Anders Hove has reported a 4.5% ownership stake in Karyopharm Therapeutics Inc. (KPTI), totaling 1,021,668 shares. This ownership is attributed through his role as manager of the general partners for two separate funds...

    Stock Titan•10/8/26•Neutral

    Karyopharm Therapeutics stock falls 13.72 percent as liquidity tightens

    Karyopharm Therapeutics (KPTI) stock fell 13.72% on October 5, 2026, due to ongoing liquidity concerns, including a $15.8 million debt deadline on October 15...

    AD HOC NEWS•10/5/26•Bearish

    A tax-related sale: Karyopharm (KPTI) accounting chief sells 378 shares at $1.19 each.

    Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), sold 378 shares of common stock at $1.19 per share on October 1...

    Stock Titan•10/2/26•Neutral

    KPTI Valuation and Fair Value

    P/E
    -0.0x
    PEG
    -0.1x
    P/B
    -0.0x
    See GNG's fair value

    KPTI Profitability: Margins, ROIC and FCF

    Gross margin
    95.9%
    Operating margin
    -67.4%
    Net margin
    -153.3%
    ROIC
    64.5%
    ROE
    -891.0%
    FCF margin
    -44.6%

    KPTI Competitors

    CompanyTicker
    Bullfrog AI Holdings, Inc. Common StockBFRG
    Neuroone Medical Technologies CorpNMTC
    Lantern Pharma IncLTRN
    Theriva Biologics Inc.TOVX
    Biovie IncBIVI
    VistaGen Therapeutics IncVTGN
    CytoMed Therapeutics Limited Ordinary SharesGDTC
    Check Cap LtdCHEK

    Sector: Healthcare

    KPTI Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    2
    Buy
    2
    Hold
    1
    Sell
    0
    Strong Sell
    0

    KPTI Bull Case vs Bear Case

    Bull case

    • KPTI earns a 64.5% return on invested capital.
    • 80.0% of KPTI's analyst ratings are Buy or Strong Buy.

    Bear case

    • KPTI has a -153.3% net profit margin.
    • KPTI's quarterly revenue changed -11.9% year over year.

    KPTI Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -6.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.31
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About KPTI

    Does KPTI pay dividends?

    Karyopharm Therapeutics Inc (KPTI) does not currently pay a regular dividend.

    What is KPTI's market cap?

    Karyopharm Therapeutics Inc (KPTI) has a market capitalization of $9.69M with a current stock price of $0.35.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In